Sir,

We are grateful to Shukla and Singh1 for their comments about our paper.2 We acknowledge their criticisms and apologize for the errors in the references that they pointed out. We had no intention of suggesting that Ocublue Plus (OP) was not approved in the European Union (EU) but, to the best of our knowledge at the time of the study in 2010, only Brilliant Peel (BP) was available in the EU for commercial use. In our study, we compared the neurosensory retinal thickness between OP and controls in the same animal. No direct comparison was done between OP and other groups like BP and ICG. The reduction in neurosensory retinal thickness in the OP group was significant when compared to the controls. This cannot be extrapolated to compare differences between OP and BP.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD